American Society of Hirudotherapy

Determinants of specificity of factor xa interaction with its physiological inhibitors

Review published in Mini reviews in medicinal chemistry (2006)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyRezaie · Mini reviews in medicinal chemistry, 2006

Abstract

Factor Xa (fXa) is the vitamin K-dependent serine protease of the prothrombinase complex (fXa, factor Va, negatively charged membrane, and calcium) which is responsible for the conversion of prothrombin to thrombin in the final stage of the coagulation cascade. The proteolytic activity of fXa in plasma is primarily regulated by three physiological inhibitors, antithrombin (AT), protein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI). The first two inhibitors belong to the serpin family of plasma inhibitors, both of which require cofactors for their effective interaction with fXa. Thus, the AT interaction with the heparin-like glycosaminoglycans on the surface of the endothelium, and the ZPI complex formation with protein Z on membrane phospholipids is required for the physiological regulation of fXa by both serpins. On the other hand, TFPI is a slow and tight-binding, Kunitz type inhibitor that is capable of rapidly inhibiting fXa independent of a cofactor. This article will review the structural features that enable fXa to specifically interact with these three inhibitors under different conditions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralReview
Indexed MeSH termsAntithrombinsEndothelium, VascularFactor VFactor XaFactor Xa InhibitorsGlycosaminoglycansHumansLipoproteinsPeptidesPlant ProteinsSerine EndopeptidasesSerpinsSubstrate SpecificityThrombin

Summary

This review examines how factor Xa interacts specifically with antithrombin (requiring heparin-like glycosaminoglycans), protein Z-dependent protease inhibitor (requiring protein Z), and tissue factor pathway inhibitor (a direct Kunitz-type inhibitor). Structural features enabling differential inhibitor recognition are discussed.

Why This Matters for Hirudotherapy

This review analyzes the structural features that determine the specificity of factor Xa interactions with its three primary physiological inhibitors: antithrombin, protein Z-dependent protease inhibitor, and tissue factor pathway inhibitor (TFPI). It discusses the distinct mechanisms of these inhibitors, noting that while the first two require specific cofactors to regulate factor Xa, TFPI acts as a Kunitz-type inhibitor that functions independently of a cofactor. While understanding these physiological regulatory mechanisms is crucial for general anticoagulant research, the article does not discuss hirudotherapy or the leech secretome. There is no mention of leeches, hirudin, or other leech-derived anticoagulants, making its relevance to the American Society of Hirudotherapy purely indirect.

Citation

Reference (Vancouver style)

Rezaie AR. Determinants of specificity of factor xa interaction with its physiological inhibitors. Mini Rev Med Chem. 2006;6(8):859-865. doi:10.2174/138955706777935017. PMID: 16918492

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.